IQM-QUANTUM-COMPUTERS
7.4.2022 17:23:05 CEST | Business Wire | Press release
IQM Quantum Computers , Hebrew University of Jerusalem and Bar-Ilan University have started a research cooperation on quantum technologies, with IQM providing commercial-grade quantum-computing hardware components to both universities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005722/en/
IQM, the Pan-European leader in quantum computers, Hebrew University of Jerusalem and Bar-Ilan University, among the leading universities in the world, announced today cooperation in quantum computing focused on research, exchange of know-how and quantum hardware.
The purpose of the cooperation is to provide the researchers at the Hebrew University of Jerusalem (in the group led by Professor Nadav Katz within its Physics Department and Quantum Information Science Center) and Bar-Ilan University (in the group led by Professor Michael Stern, of the Department of Physics) commercial-grade quantum-computing hardware developed by IQM. Researchers in these groups will conduct experiments using the IQM hardware and further advance scientific development.
The initiative also includes testing IQM’s qubit technology and conducting experiments based on its hardware. This long-term cooperation will result in significant scientific breakthroughs, several academic contributions and new product innovations. This is in line with IQM’s chosen strategy of providing its customers and partners direct access to hardware components.
Speaking about this announcement, Dr. Juha Vartiainen, COO and cofounder of IQM, said, “We are very happy to be working with both the Hebrew University of Jerusalem and Bar-Ilan University and look forward to a fruitful, long-term scientific and commercial cooperation. This announcement aligns well with our strategy to provide commercial-grade quantum-computing hardware to global research groups.”
“This cooperation is also a significant milestone for our cooperation with the world-class quantum ecosystem in Israel. As quantum computers develop further, the know-how developed in Israel—for example, around machine learning and quantum software—is going to become more critical in the future,” added Juha.
In the future, all parties also aim to extend the collaboration toward building full-stack quantum computers for scientific and commercial purposes in Israel.
“We are excited about this new collaboration with IQM and have already measured several consistently high-coherence IQM devices in our lab in Israel. This is just the beginning of a productive and fruitful joint venture,” shared Prof. Nadav Katz, director of HUJI’s Quantum Information Science Center.
Highly coherent controlled oscillations of IQM’s qubits measured in Israel (HUJI).
“We are proud to take part in a study that places Israel and its universities at the forefront of the global effort to develop quantum computers. The road is still long, but I believe that we at Bar-Ilan, together with our partners at the Hebrew University, will succeed in achieving groundbreaking results,” said Prof. Michael Stern.
About IQM Quantum Computers:
IQM is the Pan-European category leader in building quantum computers.
IQM provides on-premises quantum computers for supercomputing data centers and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique, application-specific, co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer, which will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has over 160 employees with offices in Paris, Bilbao, Munich and Espoo.
For more information: www.meetiqm.com
Recent IQM announcements:
- BioNTech Chief Operating Officer Dr. Sierk Poetting is to steer IQM global expansion as chairman .
- IQM continues its European expansion; the new French subsidiary will focus on IQM’s co-design customers in aviation, space and cybersecurity.
- IQM has opened its exclusive quantum fabrication facility in Finland.
- IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
- IQM, as part of the Q-Exa consortium , is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.
Registered office:
IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland
About the Hebrew University of Jerusalem:
The Hebrew University of Jerusalem (HUJI) is Israel’s leading academic and research institution, serving over 25,000 students from some 80 countries on 6 campuses. Founded in 1918 by luminaries including Albert Einstein, Chaim Weizmann, Sigmund Freud and Martin Buber, HUJI is ranked in the top echelon of the world’s leading universities. To date, HU faculty and alumni have won 8 Nobel Prizes, 1 Fields Medal and 1 Abel Prize—a proud tradition of innovation and excellence.
About Bar-Ilan University:
Bar-Ilan University, founded in 1955, is one of Israel’s leading institutions of higher education, uniquely combining cutting-edge scientific research with education steeped in Jewish values and social responsibility. Having grown from 70 students to close to 20,500 students, its milestone achievements in the sciences and humanities and all fields of human endeavor have made an indelible imprint on the landscape of the State of Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005722/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
